Exclusive interviews with leading policymakers that convey the true policy message that impacts markets.
Reporting on key macro data at the time of release.
Real-time insight on key fixed income and fx markets.
- Emerging MarketsEmerging Markets
Real-time insight of emerging markets in CEMEA, Asia and LatAm region
- MNI ResearchMNI Research
Actionable insight on monetary policy, balance sheet and inflation with focus on global issuance. Analysis on key political risk impacting the global markets.
- About Us
Equity futures and US yields initially dipped on Johnson & Johnson's release of their COVID-19 vaccine candidate efficacy, with the data showing 66% effectiveness in global trial results. It appears the South African variant is dragging the headline lower, with the vaccine 72% effective in the US, 66% in Latin America but just 57% in South Africa.
- Nonetheless, some positive signals are in the details of the release, with the vaccine candidate proving 85% effective in preventing severe disease across all regions studied, demonstrating complete protection against COVID-related hospitalization and death, 28 days post-vaccination.
Full Johnson & Johnson press release here.